Infliximab finds utility in management of pyoderma gangrenosum

New Orleans - The experiences of an expanding series of patients indicate infliximab (Remicade) is a valuable therapy for the management of pyoderma gangrenosum (PG), Marketa Limova, M.D., said at the annual meeting of the American Academy of Dermatology.

Related Videos
Related Content

Tips to Organize the Digital Chaos with Alina Bridges, DO

March 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Expert Tips on Alopecia Management From AAD 2023

March 20th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Treating Body Dysmorphic Disorder in Cosmetic Patients

March 20th 2023

Isotretinoin Best Practices: New Formulations, Avoiding Relapses, and More

March 20th 2023

Tips to Organize the Digital Chaos with Alina Bridges, DO

March 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Expert Tips on Alopecia Management From AAD 2023

March 20th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Treating Body Dysmorphic Disorder in Cosmetic Patients

March 20th 2023

Isotretinoin Best Practices: New Formulations, Avoiding Relapses, and More

March 20th 2023

Tips to Organize the Digital Chaos with Alina Bridges, DO

March 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Expert Tips on Alopecia Management From AAD 2023

March 20th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Treating Body Dysmorphic Disorder in Cosmetic Patients

March 20th 2023

Isotretinoin Best Practices: New Formulations, Avoiding Relapses, and More

March 20th 2023
© 2023 MJH Life Sciences

All rights reserved.